SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mira Merashli, Mohammad Hassan A. Noureldine, Imad Uthman, Munther Khamashta, Antiphospholipid syndrome: an update, European Journal of Clinical Investigation, 2015, 45, 5
  2. 2
    Daniel J. Wallace, Belimumab: Where Are We Three Years After FDA Approval?, Current Treatment Options in Rheumatology, 2015, 1, 1, 42

    CrossRef

  3. 3
    William Stohl, Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells, Arthritis & Rheumatology, 2015, 67, 3
  4. 4
    Wendy J. Komocsar, Jamie L. Blackbourne, Carolyn A. Halstead, Colleen J. Winstead, Daniel Wierda, Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations, Journal of Immunotoxicology, 2015, 1

    CrossRef

  5. 5
    M. Inui, S. Hirota, K. Hirano, H. Fujii, A. Sugahara-Tobinai, T. Ishii, H. Harigae, T. Takai, Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasmablasts developmentally in healthy individuals, International Immunology, 2015,

    CrossRef

  6. 6
    Adriano Taddeo, Laleh Khodadadi, Caroline Voigt, Imtiaz M Mumtaz, Qingyu Cheng, Katrin Moser, Tobias Alexander, Rudolf A Manz, Andreas Radbruch, Falk Hiepe, Bimba F Hoyer, Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  7. 7
    Lisa Carole Loram, Melissa Elizabeth Culp, Erin Corey Connolly-Strong, Sheila Sturgill-Koszycki, Melanocortin Peptides: Potential Targets in Systemic Lupus Erythematosus, Inflammation, 2015, 38, 1, 260

    CrossRef

  8. 8
    P. Bhargava, P. A. Calabresi, Novel therapies for memory cells in autoimmune diseases, Clinical & Experimental Immunology, 2015, 180, 2
  9. 9
    T. Alexander, A. Radbruch, F. Hiepe, Pathogenese des systemischen Lupus erythematodes, Zeitschrift für Rheumatologie, 2015, 74, 3, 183

    CrossRef

  10. 10
    Chungwen Wei, Scott Jenks, Iñaki Sanz, Polychromatic flow cytometry in evaluating rheumatic disease patients, Arthritis Research & Therapy, 2015, 17, 1

    CrossRef

  11. 11
    Jean F. Regal, Jeffrey S. Gilbert, Richard M. Burwick, The complement system and adverse pregnancy outcomes, Molecular Immunology, 2015,

    CrossRef

  12. 12
    Doruk Erkan, Cassyanne L. Aguiar, Danieli Andrade, Hannah Cohen, Maria J. Cuadrado, Adriana Danowski, Roger A. Levy, Thomas L. Ortel, Anisur Rahman, Jane E. Salmon, Maria G. Tektonidou, Rohan Willis, Michael D. Lockshin, 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends, Autoimmunity Reviews, 2014, 13, 6, 685

    CrossRef

  13. 13
    Ilse M. Rood, Julia M. Hofstra, Jeroen K.J. Deegens, Jack F.M. Wetzels, B Cell Suppression in Primary Glomerular Disease, Advances in Chronic Kidney Disease, 2014, 21, 2, 166

    CrossRef

  14. 14
    Murali Gururajan, Vishal Sindhava, Subbarao Bondada, B Cells and Immunological Tolerance, Antibodies, 2014, 3, 1, 116

    CrossRef

  15. 15
    C.-C. Liu, S.-C. Wang, C.-W. Kao, R.-K. Hsieh, M.-C. Chang, Y.-F. Chang, K.-H. Lim, C. G. Chen, B cells facilitate platelet production mediated by cytokines in patients with essential thrombocythaemia, Thrombosis and Haemostasis, 2014, 112, 3, 537

    CrossRef

  16. 16
    R. Furie, M. A. Petri, V. Strand, D. D. Gladman, Z. J. Zhong, W. W. Freimuth, Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials, Lupus Science & Medicine, 2014, 1, 1, e000031

    CrossRef

  17. 17
    Andrew E Nixon, Daniel J Sexton, Robert C Ladner, Drugs derived from phage display, mAbs, 2014, 6, 1, 73

    CrossRef

  18. 18
    Chi Chiu Mok, Emerging biological therapies for systemic lupus erythematosus, Expert Opinion on Emerging Drugs, 2014, 19, 2, 303

    CrossRef

  19. 19
    V. Strand, R. A. Levy, R. Cervera, M. A. Petri, H. Birch, W. W. Freimuth, Z. J. Zhong, A. E. Clarke, Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials, Annals of the Rheumatic Diseases, 2014, 73, 5, 838

    CrossRef

  20. 20
    John J. O’Shea, Yuka Kanno, Andrew C. Chan, In Search of Magic Bullets: The Golden Age of Immunotherapeutics, Cell, 2014, 157, 1, 227

    CrossRef

  21. 21
    A. Mathian, L. Arnaud, Z. Amoura, Physiopathologie du lupus systémique : le point en 2014, La Revue de Médecine Interne, 2014, 35, 8, 503

    CrossRef

  22. 22
    Iñaki Sanz, Rationale for B cell targeting in SLE, Seminars in Immunopathology, 2014, 36, 3, 365

    CrossRef

  23. 23
    Fabien B. Vincent, Eric F. Morand, Pascal Schneider, Fabienne Mackay, The BAFF/APRIL system in SLE pathogenesis, Nature Reviews Rheumatology, 2014, 10, 6, 365

    CrossRef

  24. 24
    Morton A Scheinberg, Dinesh Srinivasan, Renee S Martin, The potential role of blisibimod for the treatment of systemic lupus erythematosus, International Journal of Clinical Rheumatology, 2014, 9, 2, 121

    CrossRef

  25. 25
    William Stohl, Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus, Expert Opinion on Therapeutic Targets, 2014, 18, 4, 473

    CrossRef

  26. 26
    Chi Chiu Mok, Update on B-cell targeted therapies for systemic lupus erythematosus, Expert Opinion on Biological Therapy, 2014, 14, 6, 773

    CrossRef

  27. 27
    Jacques-Eric Gottenberg, Noël Lorenzo, Christelle Sordet, Arnaud Theulin, Emmanuel Chatelus, Jean Sibilia, When biologics should be used in systemic lupus erythematosus?, La Presse Médicale, 2014, 43, 6, e181

    CrossRef

  28. 28
    Jean L Scholz, Alain Diaz, Richard L Riley, Michael P Cancro, Daniela Frasca, A comparative review of aging and B cell function in mice and humans, Current Opinion in Immunology, 2013, 25, 4, 504

    CrossRef

  29. 29
    M. Schaller, J.-D. Studt, J. Voorberg, J. A. Kremer Hovinga, Acquired thrombotic thrombocytopenic purpura, Hämostaseologie, 2013, 33, 2, 121

    CrossRef

  30. 30
    Q. Cheng, I. M. Mumtaz, L. Khodadadi, A. Radbruch, B. F. Hoyer, F. Hiepe, Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis, Annals of the Rheumatic Diseases, 2013, 72, 12, 2011

    CrossRef

  31. 31
    Kathrin Pieper, Bodo Grimbacher, Hermann Eibel, B-cell biology and development, Journal of Allergy and Clinical Immunology, 2013, 131, 4, 959

    CrossRef

  32. 32
    Michelle A. Petri, Ronald F. Vollenhoven, Jill Buyon, Roger A. Levy, Sandra V. Navarra, Ricard Cervera, Z. John Zhong, William W. Freimuth, Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials, Arthritis & Rheumatism, 2013, 65, 8
  33. 33
    Moncef Zouali, Eugene A. Uy, Belimumab Therapy in Systemic Lupus Erythematosus, BioDrugs, 2013, 27, 3, 225

    CrossRef

  34. You have free access to this content34
    Preeta K. Chugh, Bhupinder S. Kalra, Belimumab: targeted therapy for lupus, International Journal of Rheumatic Diseases, 2013, 16, 1
  35. 35
    Ronald F. van Vollenhoven, Ioannis Parodis, Adrian Levitsky, Biologics in SLE: Towards new approaches, Best Practice & Research Clinical Rheumatology, 2013, 27, 3, 341

    CrossRef

  36. 36
    Ronald F. van Vollenhoven, Challenges and opportunities in SLE clinical trials, Current Opinion in Rheumatology, 2013, 25, 5, 606

    CrossRef

  37. 37
    Chaim O. Jacob, Ning Yu, Shunhua Guo, Noam Jacob, William J. Quinn, Vishal Sindhava, Michael P. Cancro, Beatrice Goilav, Chaim Putterman, Thi-Sau Migone, William Stohl, Development of Systemic Lupus Erythematosus in NZM 2328 Mice in the Absence of any Single BAFF Receptor, Arthritis & Rheumatism, 2013, 65, 4
  38. 38
    R. Fischer-Betz, M. Schneider, Empfehlungen zum Einsatz von Belimumab beim systemischen Lupus erythematodes, Zeitschrift für Rheumatologie, 2013, 72, 5, 462

    CrossRef

  39. 39
    J. Cai, X. Qing, J. Tan, P. I. Terasaki, Humoral theory of transplantation: some hot topics, British Medical Bulletin, 2013, 105, 1, 139

    CrossRef

  40. 40
    Ziv Paz, George C. Tsokos, New therapeutics in systemic lupus erythematosus, Current Opinion in Rheumatology, 2013, 25, 3, 297

    CrossRef

  41. 41
    Andrew C Chan, Timothy W Behrens, Personalizing medicine for autoimmune and inflammatory diseases, Nature Immunology, 2013, 14, 2, 106

    CrossRef

  42. 42
    M. Ramos-Casals, G. Ruiz-Irastorza, J. Jiménez-Alonso, M.A. Khamashta, Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI, Revista Clínica Española, 2013, 213, 1, 42

    CrossRef

  43. 43
    Zhi-De Hu, Yan Chen, Lei Zhang, Yi Sun, Yuan-Lan Huang, Qian-Qian Wang, Yu-Lian Xu, Sun-Xiao Chen, Qin Qin, An-Mei Deng, Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus, Clinica Chimica Acta, 2013, 425, 202

    CrossRef

  44. 44
    Masanori Yamada, Mikio Akita, Tomofumi Nakagawa, Naoki Takahashi, Akira Endo, Pascal Yoshida, Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild to moderate systemic lupus erythematosus, Journal of Drug Assessment, 2013, 1

    CrossRef

  45. 45
    Antonio La Cava, Targeting the BLyS-APRIL signaling pathway in SLE, Clinical Immunology, 2013, 148, 3, 322

    CrossRef

  46. 46
    Daniel J. Wallace, Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus, Current Rheumatology Reports, 2013, 15, 7

    CrossRef

  47. 47
    Claudio Galarza-Maldonado, María R Kourilovitch, Priscila Andrade-Sánchez, María C Durán, Elisa Asanza, Treating obstetric antiphospholipid syndrome, International Journal of Clinical Rheumatology, 2013, 8, 3, 407

    CrossRef

  48. 48
    Julia M. Hofstra, Fernando C. Fervenza, Jack F. M. Wetzels, Treatment of idiopathic membranous nephropathy, Nature Reviews Nephrology, 2013, 9, 8, 443

    CrossRef

  49. 49
    Mary K. Crow, Timothy B. Niewold, Kyriakos A. Kirou, Dubois' Lupus Erythematosus and Related Syndromes, 2013,

    CrossRef

  50. 50
    Ashley J Wilhelm, Amy S Major, Accelerated atherosclerosis in systemic lupus erythematosus: mechanisms and prevention approaches, International Journal of Clinical Rheumatology, 2012, 7, 5, 527

    CrossRef

  51. 51
    Alexis Boneparth, Anne Davidson, B-cell activating factor targeted therapy and lupus, Arthritis Research & Therapy, 2012, 14, Suppl 4, S2

    CrossRef

  52. 52
    Kirsten Fairfax, Ian R. Mackay, Fabienne Mackay, BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus, IUBMB Life, 2012, 64, 7
  53. 53
    Simon Bowman, Francesca Barone, Biologic treatments in Sjögren's syndrome, La Presse Médicale, 2012, 41, 9, e495

    CrossRef

  54. 54
    Andreea Coca, Iñaki Sanz, Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogrenʼs syndrome, Current Opinion in Rheumatology, 2012, 1

    CrossRef

  55. 55
    Joanne Bronson, Murali Dhar, William Ewing, Nils Lonberg, Annual Reports in Medicinal Chemistry Volume 47, 2012,

    CrossRef